Ken Griffin Anavex Life Sciences Corp. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.11 - $7.04 $120,834 - $206,976	29,400 Added 12.38%	266,900 $1.52 Million
Q2 2024 Aug 14, 2024	SELL	$3.39 - $5.02 $446,124 - $660,632	-131,600 Reduced 35.65%	237,500 $1 Million
Q1 2024 May 15, 2024	BUY	$4.55 - $6.75 $397,215 - $589,275	87,300 Added 30.98%	369,100 $1.88 Million
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $562,464 - $1.11 Million	111,600 Added 65.57%	281,800 $2.62 Million
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $15,720 - $22,487	-2,400 Reduced 1.39%	170,200 $1.11 Million
Q2 2023 Aug 14, 2023	SELL	$7.66 - $9.5 $2.1 Million - $2.6 Million	-273,700 Reduced 61.33%	172,600 $1.4 Million
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $220,480 - $311,375	26,500 Added 6.31%	446,300 $3.82 Million
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $1.68 Million - $3.16 Million	219,300 Added 109.38%	419,800 $3.89 Million
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $593,630 - $857,762	66,700 Added 49.85%	200,500 $2.07 Million

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $704M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.